By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem announces large scale peptide supply contracts
Bubendorf, Switzerland: –Peptide and Oligonucleotide technology specialist Bachem AG has announced that it has signed two large volume contracts to supply peptides to an undisclosed customer.
The contract order volumes are valued at CHF 25m (USD25.16m) during 2023 and CHF 150m (USD151m) for 2024.
The parties are currently in negotiations regarding further significantly higher orders for the following years. The companies have agreed not to disclose additional details and respect customer confidentiality.
Manufacturing of the peptides will primarily take place at Bachem’s new ‘Building K’ large-scale TIDES FABrication production facility currently under construction in Bubendorf, Switzerland, and due to open in 2024.
Bachem AG CEO Thomas Meier commented:
“We are excited about the recently signed agreements and the trust in our work. The need for peptide manufacturing and development capabilities across the biopharma industry is growing at a fast pace. That is why we are rapidly and consistently expanding our manufacturing base.”
Capacity expansion program
The CHF22Om TIDES FABrication Plant project for large-scale manufacture of peptides and oligonucleotides is part of the Bachem’s strategic investment program to expand capacity at all its sites, including Vionnaz (Switzerland), Torrance (USA), Vista (USA) and St. Helens (UK).
Building K construction commenced in 2021 and the facility is scheduled to open in 2024. An additional investment of CHF 150 million is budgeted for a second expansion phase. In its final form, the building will more than double manufacturing capacity at Bachem’s Bubendorf site and strongly leverage its advanced cGMP manufacturing capabilities in green chemistry and automation technologies.
Bachem envisages opening a third production facility in Switzerland by the end of the decade and recently announced it had identified a greenfield site at Sisslerfeld near Eiken in the canton of Aargau.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
Click on Bachem signs large-volume contracts for peptides to see original announcement.
Click on Bachem expands presence In Northwestern Switzerland with new production site planned In Sisslerfeld for further information.
Click on Bachems News to see latest News & Events.